Lipocalin 2 is present in the EAE brain and is modulated by natalizumab
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a demyelinating disease that causes major neurological disability in young adults. A definitive diagnosis at the time of the first episode is still lacking, but since early treatment leads to better prognosis, the search for early biomarkers is needed. Here we characterized the transcriptome of the choroid plexus (CP), which is part of the blood-brain barriers (BBBs) and the major site of cerebrospinal fluid production, in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. In addition, cerebrospinal fluid samples from two cohorts of patients with MS and with optic neuritis (ON) were analyzed to confirm the clinical relevance of the findings. Genes encoding for adhesion molecules, chemokines and cytokines displayed the most altered expression, supporting the role of CP as a site of immune-brain interaction in MS. The gene encoding for lipocalin 2 was the most up-regulated; notably, the cerebrospinal fluid lipocalin 2 levels coincided with the active phases of the disease. Immunostaining revealed that neutrophils infiltrating the CP were the source of the increased lipocalin 2 expression in this structure. However, within the brain, lipocalin 2 was also detected in astrocytes, particularly in regions typically affected in patients with MS. The increase of lipocalin 2 in the cerebrospinal fluid and in astrocytes was reverted by natalizumab treatment. Most importantly, the results obtained in the murine model were translatable into humans since patients from two different cohorts presented increased cerebrospinal fluid lipocalin 2 levels. The findings support lipocalin 2 as a valuable molecule for the diagnostic/monitoring panel of MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“In addition, the brain barriers are also of primary interest given their secretome, which, via the CSF (mostly produced by the CP) or by direct action on the brain parenchyma, may modulate brain homeostasis (Zlokovic, 2008; Marques et al., 2009a).”
Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron
Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M. A., Strong, R. K., Akira, S., & Aderem, A. (2004) · Nature · doi:10.1038/nature03104 · Cited by 1,877 · cited 8×
“The groups included in this study were controls, optic neuritis (ON) patients and patients with clinically definite relapsing remitting MS. Controls from Braga were individuals, of similar age and gender as cases that were referred to the neurology department because of neurological complaints, who were found to have…”
InfluentialReboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206 · cited 8×
“The groups included in this study were controls, optic neuritis (ON) patients and patients with clinically definite relapsing remitting MS. Controls from Braga were individuals, of similar age and gender as cases that were referred to the neurology department because of neurological complaints, who were found to have…”
BackgroundInfluentialA Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake
Devireddy, L. R., Gazin, C., Zhu, X., & Green, M. R. (2005) · Cell · doi:10.1016/j.cell.2005.10.027 · Cited by 672
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Tintoré, M., Rovira, A., Río, J., Tur, C., Pelayo, R., Nos, C., Téllez, N., Perkal, H., Comabella, M., Sastre-Garriga, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000280576.73609.c6 · Cited by 345 · cited 2×
“However, many patients with positive OCB might never develop the disease, particularly when the imaging studies are less informative (Tintore et al., 2008).”
Devireddy, L. R., Hart, D. O., Goetz, D. H., & Green, M. R. (2010) · Cell · doi:10.1016/j.cell.2010.04.040 · Cited by 295
Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice
Pedchenko, T. V., & LeVine, S. M. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00256-7 · Cited by 78 · cited 1×
“Importantly, iron seems to accumulate in human MS brain lesions and also in mice; in the latter, treatment with the iron chelator desferrioxamine reduces clinical and pathologic signs of EAE (Pedchenko and LeVine, 1998).”
24p3 and Its Receptor: Dawn of a New Iron Age?
Richardson, D. R. (2005) · Cell · doi:10.1016/j.cell.2005.12.008 · Cited by 64
Cited by
Lipocalin 2: an emerging player in iron homeostasis and inflammation
Xiao, X., Yeoh, B. S., & Vijay-Kumar, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064559 · Cited by 426
Lipocalin-2: Structure, function, distribution and role in metabolic disorders
Jaberi, S. A., Cohen, A., D’Souza, C., Abdulrazzaq, Y. M., Ojha, S., Bastaki, S., & Adeghate, E. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112002 · Cited by 345
Diverse functional roles of lipocalin-2 in the central nervous system
Jha, M. K., Lee, S., Park, D. H., Kook, H., Park, K.-G., Lee, I.-K., & Suk, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.006 · Cited by 195
Lipocalin-2 as a therapeutic target for brain injury: an astrocentric perspective
Suk, K. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.08.001 · Cited by 145
Omura, S., Sato, F., Martinez, N. E., Park, A.-M., Fujita, M., Kennett, N. J., Cvek, U., Minagar, A., Alexander, J. S., & Tsunoda, I. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00516 · Cited by 20
“Among the genes, Lcn2 was the most highly up-regulated gene, which has been reported as an immune mediator of EAE and MS (65, 66).”
Background
Metadata
- Authors
- Marques, F., Mesquita, S. D., Sousa, J. C., Coppola, G., Gao, F., Geschwind, D. H., Columba-Cabezas, S., Aloisi, F., Degn, M., Cerqueira, J. J., Sousa, N., Correia-Neves, M., & Palha, J. A.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 6
- Pages
- 33-33
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W2134494454
- Cited by
- 86
- References
- 9
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. https://app.cochat.ai/papers/10.3389/fncel.2012.00033
- The paper
- Marques, F., Mesquita, S. D., Sousa, J. C., Coppola, G., Gao, F., Geschwind, D. H., Columba-Cabezas, S., Aloisi, F., Degn, M., Cerqueira, J. J., Sousa, N., Correia-Neves, M., & Palha, J. A. (2012). Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2012.00033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.